Breast Cancer Serum-Based Detection in Radiological Diagnosis: While mammography is a widely used imaging method in the screening and diagnosis of breast cancer, there are detection and determination limitations which can negatively impact patient care and management. Nuclea has evaluated patients that have developed breast cancer as a result of an undetermined or benign diagnosis by mammography. Using these clinical outcomes data in conjunction with its DecisionDx-platform technology, Nuclea has discovered gene-, protein- and serum-based biomarkers to address the detection and evaluation of possible early stage breast cancer in patients that are found to have a suspicious lesion where the diagnosis of cancer is difficult.

Nuclea's breast, benign disease biomarkers have the potential to be highly effective when combined with existing imaging modalities. These protein signatures may have the ability to predict if a calcification, fibrocystic breast or other benign breast disease will transform into a cancerous lesion or remain benign. The protein tissue/tissue lysate signature coincides with the detection of calcifications via mammography and may predict if the calcification of a cystic breast condition will transform into a problematic cancerous lesion. This makes the breast, benign disease biomarkers the ideal companion diagnostic to justify additional imaging related studies such as secondary mammography, ultrasound or breast MRI.